Search
Avita is working towards FDA approval of its ReCell technology in the US.

Avita sells respiratory business

Perth-based regenerative medicine company Avita Medical says it will be able to focus more on its core ReCell technology after completing the sale of its respiratory business for $2.47 million.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/08/18

1 year TSR5 year TSR
167thAvita Medical52%-2%
358thMustera Property Group7%0%
364thKatana Capital6%6%
737 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

29/12/17
$75k Bought
29/12/17
$10k Bought
28/12/17
$5k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

86th↑Mustera Property Group$11.4m
87th↑Avita Medical$11.3m
89th↑Katana Capital$10.3m
90th↑Pura Vida Energy$9.4m
237 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from Avita Medical

204thTim Rooney$506k
304thAndrew Quick$366k
553rdLorraine Glover$216k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer